ADDEX THERAPEUTICS

addex-therapeutics-logo

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platf... orm targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinsonโ€™s disease levodopa induced dyskinesia (PD-LID). Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 of 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addexโ€™s GABAB PAM program for the development of drug candidates with a focus on addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsonโ€™s disease, and mGlu3 PAM for neurodegenerative disorders.

#SimilarOrganizations #People #Financial #Website #More

ADDEX THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Medical Pharmaceutical

Founded:
2002-01-01

Address:
Plan-les-ouates, Geneve, Switzerland

Country:
Switzerland

Website Url:
http://www.addextherapeutics.com

Total Employee:
11+

Status:
Active

Contact:
+41228841555

Email Addresses:
[email protected]

Total Funding:
189.43 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

piqur-therapeutics-logo

PIQUR Therapeutics

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.


Current Advisors List

antoine-papiernik_image

Antoine Papiernik Board of Directors @ Addex Therapeutics
Board_member

francesco-rubertis_image

Francesco Rubertis Investor @ Addex Therapeutics
Board_member

hoyoung-huh_image

Hoyoung Huh Board of Directors @ Addex Therapeutics
Board_member

werner-henrich_image

Werner Henrich board of directors @ Addex Therapeutics
Board_member

jake-nunn_image

Jake Nunn Board Member @ Addex Therapeutics
Board_member
2018-06-01

raymond-hill_image

Raymond Hill Board Member @ Addex Therapeutics
Board_member

Current Employees Featured

robert-lutjens_image

Robert Lutjens
Robert Lutjens Head of Discovery โ€“ Biology @ Addex Therapeutics
Head of Discovery โ€“ Biology
2015-05-01

jean-philippe-rocher_image

Jean-Philippe Rocher
Jean-Philippe Rocher Head of Discovery - Chemistry @ Addex Therapeutics
Head of Discovery - Chemistry

tim-dyer_image

Tim Dyer
Tim Dyer CEO @ Addex Therapeutics
CEO
2013-06-01

roger-g-mills_image

Roger G. Mills
Roger G. Mills Chief Medical Officer @ Addex Therapeutics
Chief Medical Officer
2016-11-01

vincent-lawton_image

Vincent Lawton
Vincent Lawton Vice Chairman @ Addex Therapeutics
Vice Chairman
2011-07-01

Founder


tim-dyer_image

Tim Dyer

Stock Details


Company's stock symbol is SWX:ADXN

Investors List

armistice-master-fund-ltv_image

Armistice Master Fund LTV

Armistice Master Fund LTV investment in Post-IPO Equity - Addex Therapeutics

indivior_image

Indivior

Indivior investment in Post-IPO Equity - Addex Therapeutics

innosuisse_image

InnoSuisse

InnoSuisse investment in Grant - Addex Therapeutics

national-institute-on-drug-abuse-nida_image

National Institute on Drug Abuse (NIDA)

National Institute on Drug Abuse (NIDA) investment in Grant - Addex Therapeutics

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Post-IPO Equity - Addex Therapeutics

hercules-bioventure-partners_image

Hercules Bioventure Partners

Hercules Bioventure Partners investment in Post-IPO Equity - Addex Therapeutics

the-michael-j-fox-foundation_image

Michael J. Fox Foundation

Michael J. Fox Foundation investment in Grant - Addex Therapeutics

hercules-bioventure-partners_image

Hercules Bioventure Partners

Hercules Bioventure Partners investment in Post-IPO Equity - Addex Therapeutics

armistice-capital_image

Armistice Capital

Armistice Capital investment in Post-IPO Equity - Addex Therapeutics

biotechnology-value-fund_image

Biotechnology Value Fund

Biotechnology Value Fund investment in Post-IPO Equity - Addex Therapeutics

Official Site Inspections

http://www.addextherapeutics.com Semrush global rank: 3.66 M Semrush visits lastest month: 3.86 K

  • Host name: od-d1e2fa.infomaniak.ch
  • IP address: 83.166.152.52
  • Location: Switzerland
  • Latitude: 47.1449
  • Longitude: 8.1551
  • Timezone: Europe/Zurich

Loading ...

More informations about "Addex Therapeutics" on Search Engine